Innovations and recent trends in the treatment of ADHD

References

• Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG, Hurley BJ. Trends in environmentally related childhood illnesses. Pediatrics113, 1133–1140 (2004).
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder – United States, 2003. MMWR Morb. Mortal. Wkly Rep.54(34), 842–847 (2005).
   PubMedGoogle Scholar
• Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J. Am. Acad. Child Adolesc. Psychiatry29, 546–557 (1990).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone S, Milberger S et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch. Gen. Psychiatry53, 437–446 (1996).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler LA, Barkley R et al. Patterns and predictors of attention deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol. Psychiatry57 (11), 1442–1451 (2005).
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol.111, 279–289 (2002).
   PubMed Web of Science ®Google Scholar
• Biederman J, Kwon A, Aleardi M et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am. J. Psychiatry162(6), 1083–1089 (2005).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics111(1), 179–185 (2003).
   PubMed Web of Science ®Google Scholar
• Voeller KK. Attention-deficit hyperactivity disorder (ADHD). J. Child Neurol.19(10), 798–814 (2004).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th Edition), Text revision. American Psychiatric Association, DC, USA (2000).
   Google Scholar
• Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol. Psychiatry57, 1336–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Perlis RH, Doyle AE et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry57(11), 1313–1323 (2005).
   PubMed Web of Science ®Google Scholar
• McGough, JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol. Psychiatry57(11), 1367–1373 (2005).
   PubMed Web of Science ®Google Scholar
• Willcutt EG, Pennington BF, DeFries JC. Twin study of the etiology of comorbidity between reading disability and attention-deficit/hyperactivity disorder. Am. J. Med. Genet.96, 293–301 (2000).
   PubMed Web of Science ®Google Scholar
• Hudziak JJ, Heath AC, Madden PF et al. Latent class and factor analysis of DSM-IV ADHD: a twin study of female adolescents. J. Am. Acad. Child Adolesc. Psychiatry37, 848–857 (1998).
   PubMed Web of Science ®Google Scholar
• Voeller KK. Attention-deficit hyperactivity disorder (ADHD). J. Child Neurol.19(10), 798–814 (2004).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet366(9481), 237–248 (2005).
   PubMed Web of Science ®Google Scholar
• Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol. Psychiatry57(11), 1215–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Kreppner JM, O’Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? J. Abnorm. Child Psychol.29, 513–528 (2001).
   PubMed Web of Science ®Google Scholar
• Castellanos FX, Lee PP, Sharp W et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA288, 1740–1748 (2002).
   PubMed Web of Science ®Google Scholar
• Durston S, Hulshoff Pol HE, Schnack HG et al. Magnetic resonance imaging of boys with attention-deficit/hyperactivity disorder and their unaffected siblings. J. Am. Acad. Child Adolesc. Psychiatry43, 332–340 (2004).
   PubMed Web of Science ®Google Scholar
• Durston S, Tottenham NT, Thomas KM, et al. Differential patterns of striatal activation in young children with and without ADHD. Biol. Psychiatry53, 871–878 (2003).
   PubMed Web of Science ®Google Scholar
• Wells KC, Pelham WE, Kotkin RA et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J. Abnorm. Child Psychol.28(6), 483–505 (2000).
   PubMed Web of Science ®Google Scholar
• Brown TE. Disorders that may accompany ADD syndrome. In: Attention Deficit Disorder. The Unfocused Mind in Children and Adults. Yale University Press Health and Wellness, CT, USA 200–203 (2005).
   Google Scholar
• Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adoles. Psychiatry42(9), 1015–1037 (2003).
   PubMed Web of Science ®Google Scholar
• Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J. Am. Acad. Child Adolesc. Psychiatry36, S85–S121 (1997).
   Web of Science ®Google Scholar
• Barber SJ. Self-perception in children with attention deficit/hyperactivity disorder. Pediatr. Nurs.20(4), 235–245 (2005).
   Google Scholar
• Mariani MA, Barkley RA. Neuropsychological and academic functioning in preschool boys with attention deficit hyperactivity disorder. Dev. Neuropsychol.13, 111–129 (1997).
   Web of Science ®Google Scholar
• Shelton TL, Barkley RA, Crosswait C. Psychiatric and psychological morbidity as a function of adaptive disability in preschool children with aggressive and hyperactive-impulsive-inattentive behavior. J. Abnorm. Child Psychol.26, 475–494 (1998).
   PubMed Web of Science ®Google Scholar
• Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA285(1), 60–66 (2001).
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Vitiello B, Abikoff HB, Kollins S, Wigal S, Swanson JM. Outcome results from the NIMH, multi-site, preschool ADHD treatment study (PATS). Presented at: 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry Washington DC, USA, October 19–24 (2004).
   Google Scholar
• Pliszka SR, Crimson L, Hughes CW et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry45(6), 642–657 (2006).
   PubMed Web of Science ®Google Scholar
• Michelson D. Active comparator studies in the atomoxetine clinical development program. Presented at: 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, USA, October 19–24 (2004).
   Google Scholar
• Wigal S, McGough J, McCracken JT, Clark T, Mays D, Tulloch S. Analog classroom study of amphetamine XR and atomoxetine for ADHD. Presented at: 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, USA, October 19–24 (2004).
   Google Scholar
• Faraone SV, Spencer TJ, Aleadri M, Pagano C, Biederman J. Comparing the efficacy of medications used for ADHD using meta-analysis. Presented at: 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA, May 17–22 (2003).
   Google Scholar
• Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.Int. J. Neuropsychopharmacol.7, 77–97 (2004).
   PubMed Web of Science ®Google Scholar
• Pierce DM, Dixon CM, Wigal SB, McGough JJ. Pharmacokinetics of methylphenidate transdermal system in children with attention-deficit hyperactivity disorder. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Pelham WE Jr, Manos MJ, Ezzell CE et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD.J. Am. Acad. Child Adolesc. Psychiatry44(6), 522–529 (2005).
   PubMed Web of Science ®Google Scholar
• Findling RL, Lopez FA. The effects of transdermal methylphenidate with reference to OROS methylphenidate in ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Pelham WE, Burrows-MacLean L, Gnagy EM et al. Transdermal methylphenidate, behavioral and combined treatment for children with ADHD. Exp. Clin. Psychopharmacol.13(2), 111–126 (2005).
   PubMed Web of Science ®Google Scholar
• Wigal S, McGough JJ, Abikoff H, Turnbow JM, Posner K, Moon E. Behavioral effects of methylphenidate transdermal system in children with ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Mays DA, Findling RL. Methylphenidate transdermal system. J. Am. Acad. Child Adolesc. Psychiatry44(12), 1223 (2005).
   PubMed Web of Science ®Google Scholar
• Keating GM, Raffin MJ. Modafinil. A review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs19(9), 785–803 (2005).
   PubMed Web of Science ®Google Scholar
• Biederman J, Swanson JM, Wigal SB et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics116(6), E777–E784 (2005).
   PubMed Web of Science ®Google Scholar
• Mignot E, Nishino S, Guilleminault C et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep17(5), 436–437 (1994).
   PubMed Web of Science ®Google Scholar
• Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr. Neurol.29(2), 136–142 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J. Child Adolesc. Psychopharmacol.10(4), 311–320 (2000).
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Greenhill LL, Biederman J et al. Safety of modafinil film-coated tablets in the treatment of attention-deficit/hyperactivity disorder. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Hechtman L, Turgay A, Weiss, M et al. Double-blind, crossover comparison of two methylphenidate formulations in childhood ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Jain U, Ahmed T, Weiss M et al. Double-blind, placebo-controlled, crossover study of controlled-release methylphenidate in adult ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr.8(4), 253–258 (2003).
   PubMed Web of Science ®Google Scholar
• Posey DJ, Puntney JL, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J. Child Adolesc. Psychopharmacol.14(2), 233–241 (2004).
   PubMed Web of Science ®Google Scholar
• Easton N, Shah Y, Marshall F, Marsden C. Guanfacine produces alterations in BOLD contrast, as measured by fMRI. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Sagvolden T. d-Amphetamine and guanfacine improve behavioral symptoms in a rat model of ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Scahill L, Chappell PB, Kim YS et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. J. Psychiatry158, 1067–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent. Psychopharmacol.6(5), 262–276 (2005).
   PubMedGoogle Scholar
• Westfall T, Grant H, Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen. Pharmacol.14, 321–325 (1983).
   PubMedGoogle Scholar
• Conners CK, Levin ED, Sparrow E et al. Nicotine and attention in adult attention deficit hyperactivity disorder. Psychopharmacol. Bull.32, 67–73 (1996).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psychiatry156, 1931–1937 (1999).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Waxmonsky J, Scott M et al. An open trial of adjunctive donepezil in ADHD. J. Child Adolesc. Psychopharmacol.15, 947–955 (2005).
   PubMed Web of Science ®Google Scholar
• Mick E. A double blind comparison of galantamine Hbr and placebo in adults with ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Wilens T, West S, Adler L et al. A neuronal nicotine receptor modulator for ADHD in adults: results of a pilot study. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Arnold LE. DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.15(4), 619–627 (2005).
   PubMed Web of Science ®Google Scholar
• Sandyk R. Zinc deficiency in attention deficit/hyperactivity disorder. Inter. J. Neurosci.52, 239–241 (1990).
   PubMed Web of Science ®Google Scholar
• Kozielec T, Starobrat-Hermelin B, Kotkowiak L. Deficiency of certain trace elements in children with hyperactivity (Polish). Psychiatr. Pol.28(3), 345–353 (1994).
   PubMedGoogle Scholar
• Bekaroglu M, Yakup A, Yusof G et al. Relationships between serum free fatty acids and zinc and ADHD. J. Child Psychol. Psychiatry37, 225–227 (1996).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Bozzolo H, Hollway J et al. Serum zinc correlates with patient-and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.15(4), 628–636 (2005).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Mohammadi M-R, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit/hyperactivity disorder in children. A double-blind randomized trial. BMC Psychiatry4, 9 (2004).
   PubMed Web of Science ®Google Scholar
• Bilici M, Yildirim F, Kandil S et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry28, 181–190 (2004).
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J, Conners CK, Sarkis EH et al. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. J. Am. Acad. Child Adolesc. Psychiatry41, 914–990 (2002).
   PubMed Web of Science ®Google Scholar
• Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc. Psychiatric Clin. N. Am.15, 13–50 (2006).
   PubMed Web of Science ®Google Scholar
• Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry44, 428–443 (2005).
   PubMed Web of Science ®Google Scholar